Ads
related to: sorafenib price- Co-Pay Program
Learn About A $0 Co-Pay Program
For Eligible CABOMETYX® Patients.
- Prescribing Information
Download The Prescribing
Information For CABOMETYX®.
- Efficacy & Safety Data
Read More About Efficacy & Safety
Data For CABOMETYX®.
- CABOMETYX® Trial Results
Visit To See The Trial Results
For CABOMETYX®.
- Co-Pay Program
Search results
Results From The WOW.Com Content Network
Sorafenib, sold under the brand name Nexavar, [3] is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
Sorafenib, co-developed and co-marketed with Bayer and sold under the trade name Nexavar, is a drug approved in the United States for the treatment of advanced renal cell carcinoma (kidney cancer) in 2005, and for the treatment of inoperable hepatocellular carcinoma, the most common form of liver cancer, in 2007.
President Donald Trump rolled back a Biden administration executive order aimed at lowering prescription drug prices, including an effort to make more generic drugs available to Medicare patients ...
"Lowering drug prices is a focus area for both Republicans and Democrats, and Chinese CDMOs [manufacturers] such as Wuxi Group play a key role as it helps the US pharma cut costs by 30-60%.
Last year, Medicare reached agreements to lower prices on the 10 costliest drugs, including Eliquis, a blood thinner; Imbruvica, a blood cancer treatment; and NovoLog, a diabetes medication.
Regorafenib and at least one of its analogs, sorafenib, are potent inhibitors of Soluble epoxide hydrolase (sEH). [ 11 ] sEH metabolizes, and in general thereby inactivates, epoxyeicosatrienoic acids (EETs), epoxydocosapentaenoic acids (EDPs), epoxyeicosatetraenoic acids (EEQs), and other epoxy polyunsaturated fatty acids that are made by ...
Ad
related to: sorafenib price